[ad_1]
Tilray (NASDAQ: TLRY)
In summary, the medical marijuana company Tilray has been the subject of many titles in recent months, both with respect to developments in the pharmaceutical sector and the sharp increase in its market capitalization. The Canadian company, which generated only $ 20 million in revenue last year, has seen its market capitalization rise to more than $ 13 billion in recent months.
Tilray recorded one of its best days on Wall Street in September after the announcement by the Drug Enforcement Administration of the authorization to import marijuana into the United States for the purpose of medical research. The Vancouver Island-based Canadian company plans to collaborate with the University of California San Diego's Medical Cannabis Research Center to study the safety, tolerability, and effectiveness of marijuana in the treatment of a neurological disorder.
"The pace and change is accelerating rapidly and we are witnessing the emergence of well-funded professional brands," CEO Brendan Kennedy told CNBC on Wednesday. "It's a global opportunity and we think we have the benefit of the first comer."
Founded in 2013, Tilray was incorporated as Privateer Holdings, a Kennedy-based private equity firm. Privateer, which still holds about 80 percent of the company, announced earlier this year that it has raised $ 200 million to invest in cannabis brands.
Peter Thiel's Founders Fund, a billion dollar investor, became the first institutional investor in the cannabis industry through Privateer's Series 75 financing round of financing in December 2014, according to the company's website.
Equity statistics:
- Shares available to investors (float): 21.7 million
- Short-term interest: 13% of floating stock
- Price move since July 19th: approx. 760 percent.
Forest Cover Growth (NYSE: CGC)
Canopy Growth, headquartered in Smiths Falls, Canada, is another emerging leader in the cannabis field. Headquartered about an hour south-west of Ottawa, the company's stock gathered earlier this week after announcing plans to acquire a US-based hemp research company. .
Canopy Growth said its purchase of Ebbu, based in Evergreen, Colorado, would "complement and accelerate" its ambitions to expand into new types of consumer products, including more productive plants and technology. necessary to incorporate cannabidiol into consumer goods.
Canopy was the first publicly traded cannabis company in North America in 2014 under the leadership of co-CEO Bruce Linton. The company markets medical marijuana products – including flowers and oils – in Canada, Germany and the Czech Republic. She recently strengthened her relationship with brewer Corona Constellation Brands.
The beer brewer is investing approximately $ 4 billion in the Canadian marijuana growers to expand its strategic portfolio, while beer consumption in the United States is declining.
"Better" will be a big argument, "Linton told CNBC's Deirdre Bosa in a Canopy store in Newfoundland on Wednesday." People will start to realize that the product they're getting from the reseller Illegal comes officially, nowhere. "
Equity statistics:
- Shares available for investors (float): 204 million
- Short-term interest: 6.8% of floating stock
- Price move since July 19th: approx. 100 per cent.
Aurora Cannabis (Toronto: ACB)
Aurora, another Vancouver-based producer, has made headlines in recent weeks as he and Coca-Cola have been discussing how to develop weed-infused drinks.
Some analysts have speculated that such a partnership would likely focus on the development of health-focused beverages aimed at alleviating inflammation, pain and cramps, a product that may appeal to athletes. The company said later in September that it did not have a formal partnership agreement with a beverage company.
The New York Stock Exchange has certified its approval for the listing and registration of Aurora shares on Wednesday, according to a document filed by the Securities and Exchange Commission. Aurora shares have increased 390% in the last 12 months in Toronto.
- Shares available to investors (float): 919 million
- Short-term interest: 2.1% of floating stock
- Price move since July 19th: approx. 71 percent.
– CNBC
Berkeley Lovelace, Jr.
Contributed reports.
Source link
